您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > HDAC-IN-31
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
HDAC-IN-31
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
HDAC-IN-31图片
CAS NO:1916505-13-9
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
HDAC-IN-31 是一种有效、选择性和具有口服活性的HDAC抑制剂,HDAC1、HDAC2、HDAC3、HDAC8 的IC50值分别为 84.90, 168.0, 442.7, >10000 nM。 HDAC-IN-31 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在在 G2/M 期。HDAC-IN-31 显示出良好的抗肿瘤功效。HDAC-IN-31 具有研究弥漫性大B细胞淋巴瘤的潜力。
生物活性

HDAC-IN-31 is a potent, selective and orally activeHDACinhibitor withIC50s of 84.90, 168.0, 442.7, >10000 nM forHDAC1,HDAC2,HDAC3,HDAC8, respectively. HDAC-IN-31 inducesapoptosisand cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma[1].

IC50& Target[1]

HDAC1

84.90 nM (IC50)

HDAC2

168.0 nM (IC50)

HDAC3

442.7 nM (IC50)

HDAC8

>10000 nM (IC50)

体外研究
(In Vitro)

HDAC-IN-31 (compound 24g) (2 μM) shows growth-inhibitory activities with the inhibition rate of 2.32%, 44.01%, 48.53%, 64.94% for TMD-8, HCT 116, A549, MDA-MB-231 cells[1].
HDAC-IN-31 (1 μM) shows selectivity with the IC50s of 84.9, 168.0, 442.7, >10000 nM for HDAC 1, HDAC 2, HDAC 3, HDAC 8, and 81.20%, 84.43%, 88.07%, 92.34%, 96.88%, 91.98% enzyme activity for HDAC4, HDAC 5,HDAC 7, HDAC9, HDAC 6, HDAC 11, respectively[1].
HDAC-IN-31 (2.5, 5, 7.5, 10 μM; 24 h) increases the expression of HDAC1, Ace-H3, Ace-H4, Cleaved PARP, Cleaved Caspase-3 in a dose-dependent manner[1].
HDAC-IN-31 (0-4 μM; 24 h)induce apoptosis and cell cycle arrests in G2/M phase in a dose-dependent manner[1].

Cell Proliferation Assay[1]

Cell Line:MDA-MB-231, A549, NCI-H460, HCT-116,SK-OV-3, HT-29, COLO 678, NCI-H441, 22Rv1, 786-O, TMD-8, DOHH-2, CCRF-CEM, SU-DHL-2, REC-1, MOLT-4, HUT-78, RS4;11 cells
Concentration:0-20 μM
Incubation Time:72 h
Result:Showed a broad spectrum of antitumor activity with the IC50s of 2.29, 2.85, 1.58, 1.16, 3.17, 2.41, 8.02, 2.62, 1.14, 0.60, 0.31, 0.39, 0.48, 0.51, 0.33, 0.38, 0.80, 0.47 μM for MDA-MB-231, A549, NCI-H460, HCT-116, SK-OV-3, HT-29, COLO 678, NCI-H441, 22Rv1, 786-O, TMD-8, DOHH-2, CCRF-CEM, SU-DHL-2, REC-1, MOLT-4, HUT-78, RS4;11 cells, respectively.

Western Blot Analysis[1]

Cell Line:TMD-8 cells
Concentration:2.5, 5, 7.5, 10 μM
Incubation Time:24 h
Result:Promoted the HDAC1, HDAC2, HDAC3 substrate Ace-H3 and Ace-H4 acetylation with a dose-dependent manner.

Apoptosis Analysis[1]

Cell Line:TMD-8 cells
Concentration:0.5, 1, 2, 4 μM
Incubation Time:24 h
Result:Induced cell apoptosis at a concentration-dependent manner.

Cell Cycle Analysis[1]

Cell Line:TMD-8 cells
Concentration:250, 500, 1000 nM
Incubation Time:24 h
Result:Arrested the cell cycle at G2/M phase in a dose-dependent manner.
体内研究
(In Vivo)

HDAC-IN-31 (2 mg/kg for i.v.; 10, 100 mg/kg for p.o.) shows good bioavailability with a significant dose dependent manner[1].
HDAC-IN-31 (50, 100 mg/kg; p.o, daily for 21 consecutive days) shows good antitumor efficacy in a TMD-8 xenograft model without obvious toxicity[1].
Pharmacokinetic Parameters of HDAC-IN-31 in mice[1].

ParametersUnit24 g (25 mg/kg)
Cmaxng·h·mL-13100±231
T1/2(po)h4.4±0.3
AUC0-inf(iv)ng·h·mL-11040±142
AUC0-inf(po)ng·h·mL-15180±252
MRTPOh2.6±0.4
F%39.9±2.1
ICR mouse; 2 mg/kg for i.v.; 25 mg/kg for p.o.[1].
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models[1].
ParametersUnitpo (25 mg/kg)po (50 mg/kg)po (100 mg/kg)
Cmaxng·h·mL-11700±31714700±102410700±1001
AUC0-tng·h·mL-11220±2429710±3149740±230
AUC0-infng·h·mL-11230±1659730±3419770±332
MRT0-th0.750±0.0430.812±0.0231.43±0.56
MRT0-infh0.805±0.0860.821±0.0411.51±0.32
Mouse; 25, 50, 100 mg/kg for p.o.[1].
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models[1].
PK parametersUnitiv (2 mg/kg)po (10 mg/kg)po (100 mg/kg)
Cmaxng·h·mL-13960±41358300±1352
T1/2h0.427±0.0161.31±0.271.63±0.52
AUC0-infng·h·mL-11250±1322670±28657200±1047
MRTh0.402±0.0320.919±0.0520.897±0.041
CLmL·kg·min-127.2±1.2
F%45.6±1.291.8±2.3
ICR mice; 2 mg/kg for i.v.; 10, 100 mg/kg for p.o.[1].
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models[1].
PK parametersUnitMonkeyDog
iv (1 mg/kg)po (10 mg/kg)iv (1 mg/kg)po (10 mg/kg)
Cmaxng·h·mL-18520±3014740±243
T1/2h4.31±0.569.14±0.321.65±0.411.51±0.33
AUC0-infng·h·mL-115700±184253200±12412550±36515100±2004
MRTh3.41±0.128.28±0.322.26±0.412.71±0.32
CLmL·kg·min-11.35±0.216.72±0.35
VdssL·kg-10.34±0.220.55±0.04
F%27.6±2.158.9±1.2
Dogs and monkeys; 1 mg/kg for i.v., 10 mg/kg for p.o. for monkey; 1 mg/kg for i.v., 10 mg/kg for p.o. for dog[1].

Animal Model:ICR mice[1]
Dosage:2 mg/kg for i.v.; 25 mg/kg for p.o.(DMSO/PEG200/saline = 20:20:60, v/v/v)
Administration:I.v. or p.o.
Result:Showed high oral bioavailability (F=40%).
Animal Model:Mouse[1]
Dosage:25, 50, 100 mg/kg
Administration:P.o.
Result:Did not exhibit a significant dose dependent for oral administration.
Animal Model:ICR mice[1]
Dosage:2, 10, 100 mg/kg (into the form of hydrochloride)
Administration:2 mg/kg for i.v.; 10, 100 mg/kg for p.o.
Result:Showed good bioavailability with a significant dose dependent.
Animal Model:Dogs and monkeys[1]
Dosage:1, 10 mg/kg
Administration:1 mg/kg for i.v.; 10 mg/kg for p.o.
Result:Showed good pharmacokinetic characteristics for different species.
Animal Model:5-6 weeks, female CB.17 SCID mice (TMD-8 tumor xenografts)[1]
Dosage:50, 100 mg/kg
Administration:P.o, daily for 21 consecutive days
Result:Inhibited the tumor growth with the inhibition rate of 77% and had no significant effect on the internal organs of mice at 100 mg/kg/d.
分子量

412.48

Formula

C25H24N4O2

CAS 号

1916505-13-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.